Triple

T1168577
Position Surface form Disambiguated ID Type / Status
Subject Eli Lilly and Company E24856 entity
Predicate notableProduct P1448 FINISHED
Object Emgality
Emgality is a prescription monoclonal antibody medication used for the prevention and treatment of migraine and cluster headaches.
 E133653 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Emgality | Statement: [Eli Lilly and Company, notableProduct, Emgality]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Emgality
Context triple: [Eli Lilly and Company, notableProduct, Emgality]
  • A. Anpezan
    Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
  • B. Xolair
    Xolair is a monoclonal antibody medication used to treat moderate to severe allergic asthma and chronic spontaneous urticaria by targeting immunoglobulin E (IgE).
  • C. Darzalex
    Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
  • D. Stelara
    Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
  • E. Vumerity
    Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Emgality
Triple: [Eli Lilly and Company, notableProduct, Emgality]
Generated description
Emgality is a prescription monoclonal antibody medication used for the prevention and treatment of migraine and cluster headaches.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: Emgality
Target entity description: Emgality is a prescription monoclonal antibody medication used for the prevention and treatment of migraine and cluster headaches.
  • A. Anpezan
    Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
  • B. Xolair
    Xolair is a monoclonal antibody medication used to treat moderate to severe allergic asthma and chronic spontaneous urticaria by targeting immunoglobulin E (IgE).
  • C. Darzalex
    Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
  • D. Stelara
    Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
  • E. Vumerity
    Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a494082a7c819095004f423f294a64 completed March 1, 2026, 7:31 p.m.
NER Named-entity recognition batch_69a4bccef84481908864e819884af86c completed March 1, 2026, 10:25 p.m.
NED1 Entity disambiguation (via context triple) batch_69ac668562788190ac5f8d081a46b2ee completed March 7, 2026, 5:55 p.m.
NEDg Description generation batch_69ac67a07f28819096fcd7b767e07a63 completed March 7, 2026, 6 p.m.
NED2 Entity disambiguation (via description) batch_69ac6826ef4c81909fc077bfba22b16f completed March 7, 2026, 6:02 p.m.
Created at: March 1, 2026, 7:45 p.m.